AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8872406 — intervention group
Group type: COMPARATOR
Intervention: All groups after four treatments
Number of subjects: 65
Study 1379054 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine 2 mg twice a day for 5 days
Number of subjects: 15
Study 1379054 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg once a day for 5 days
Number of subjects: 15
Study 1379054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1379054 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine and Loratadine
Number of subjects: 15
Study 6741683 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth anesthesia with 2% lidocaine
Number of subjects: 0
Study 6741683 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth and pharyngeal anesthesia with 2% lidocaine
Number of subjects: 0
Study 6741683 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper and lower airway anesthesia with 2% lidocaine and inhalation of 4% lidocaine (60 breaths)
Number of subjects: 0
Study 6741683 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 0
Study 30582246 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% EDTA solution + Saline solution (SSE)
Number of subjects: 60
Study 30582246 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.25% Ca(OCl)2 (CH)
Number of subjects: 60
Study 30582246 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl (SH)
Number of subjects: 60
Study 30582246 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl + 17% EDTA (SHE)
Number of subjects: 60
Study 30582246 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.25% Ca(OCl)2 + 17% EDTA (CHE)
Number of subjects: 60
Study 30582246 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (SS) (control)
Number of subjects: 60
Study 27918778 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 247
Study 27918778 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 247
Study 27918778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study 25810108 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulating catheter
Number of subjects: 58
Study 25810108 — intervention group
Group type: COMPARATOR
Intervention: Standard catheter
Number of subjects: 58
Study 24555913 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA 1 g/day
Number of subjects: 54
Study 24555913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 22241059 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise training (8 weeks)
Number of subjects: 16
Study 19574865 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release epidural morphine (EREM) 15 mg administered alone
Number of subjects: 144
Study 19574865 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release epidural morphine (EREM) 15 mg administered 15, 30, or 60 mins after bupivacaine (20 mL 0.25%)
Number of subjects: 144
Study 19574865 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release epidural morphine (EREM) groups (with/without prior bupivacaine)
Number of subjects: 144
Study 19574865 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine + placebo (normal saline) administered 15, 30, or 60 mins after bupivacaine
Number of subjects: 144
Study 19574865 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups receiving EREM after bupivacaine
Number of subjects: 144
Study 17301625 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PCI
Number of subjects: 1351
Study 17301625 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolysis
Number of subjects: 1351
Study 15121929 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic application of emollient ointment twice a day through day 14 (P)
Number of subjects: 1191
Study 15121929 — intervention group
Group type: COMPARATOR
Intervention: Routine skin care (R)
Number of subjects: 1191
Study 11213858 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 0
Study 11213858 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteplase
Number of subjects: 0
Study 11213858 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 0
Study 11213858 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteplase and Tenecteplase
Number of subjects: 0
Study 11213858 — intervention group
Group type: EXPERIMENTAL
Intervention: Current trials
Number of subjects: 0
Study 9656196 — intervention group
Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 132
Study 9656196 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP/VIA
Number of subjects: 132
Study 8003791 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% podophyllotoxin cream
Number of subjects: 150
Study 8003791 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% podophyllotoxin cream
Number of subjects: 150
Study 8003791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 8003791 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% and 0.5% podophyllotoxin creams
Number of subjects: 150
Study 2523681 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nebulized solution 0.4 mg
Number of subjects: 42
Study 2523681 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nebulized solution 0.6 mg
Number of subjects: 42
Study 2523681 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide metered-dose inhaler 40 micrograms
Number of subjects: 42
Study 2523681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 2523681 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nebulized solution 0.4 mg and 0.6 mg
Number of subjects: 42
Study 304691 — intervention group
Group type: EXPERIMENTAL
Intervention: Kallikrein inhibitor (protease-inhibitor)
Number of subjects: 0
Study 304691 — intervention group
Group type: COMPARATOR
Intervention: Control (no kallikrein inhibitor)
Number of subjects: 0
Study 31668142 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascial Manipulation® (FM®) method, 3 weekly sessions by PtA
Number of subjects: 71
Study 31668142 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 71
Study 31192505 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic testing for T1D susceptibility SNPs or family history screening, followed by participation in a randomized controlled trial for tolerance induction with oral insulin.
Number of subjects: 330000
Study 31192505 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trial for tolerance induction with oral insulin.
Number of subjects: 330000
Study 31192505 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening program GPPAD-02.
Number of subjects: 330000
Study 28784729 — intervention group
Group type: EXPERIMENTAL
Intervention: $50 cash incentive
Number of subjects: 0
Study 28784729 — intervention group
Group type: EXPERIMENTAL
Intervention: $25 cash incentive
Number of subjects: 0
Study 28784729 — intervention group
Group type: EXPERIMENTAL
Intervention: $0 cash incentive
Number of subjects: 0
Study 28784729 — intervention group
Group type: COMPARATOR
Intervention: Nonincentivized control group
Number of subjects: 0
Study 23963636 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based walking intervention plus brief telephone counseling (n = 20)
Number of subjects: 32
Study 23963636 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (n = 12)
Number of subjects: 32
Study 24560287 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized Arterial Input Function (iAIF)
Number of subjects: 17
Study 24560287 — intervention group
Group type: COMPARATOR
Intervention: Cohort-based Arterial Input Function (cAIF)
Number of subjects: 17
Study 24560287 — intervention group
Group type: EXPERIMENTAL
Intervention: iAIF
Number of subjects: 17
Study 22563179 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal ileus tube
Number of subjects: 186
Study 22563179 — intervention group
Group type: COMPARATOR
Intervention: Nasogastric tube (NGT)
Number of subjects: 186
Study 19349586 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Care Program for Families and Friends (GCPFF)
Number of subjects: 308
Study 17189867 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone + Insulin
Number of subjects: 53
Study 15108771 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard tacrolimus (trough levels of 10-15 ng/mL) plus reduced sirolimus (trough levels of 5-10 ng/mL) (Group I)
Number of subjects: 39
Study 15108771 — intervention group
Group type: COMPARATOR
Intervention: Reduced tacrolimus (trough levels of 5-10 ng/mL) plus standard sirolimus (trough levels of 10-15 ng/mL) (Group II)
Number of subjects: 39
Study 11393298 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9730094 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 hours in a supine lying-down position with 30 degrees of arm elevation
Number of subjects: 45
Study 9730094 — intervention group
Group type: COMPARATOR
Intervention: No arms-at-side lying-down position after 2 hours awake or overnight sleep with bed-head elevated or not
Number of subjects: 45
Study 7506878 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame (APM) 34 mg/kg single morning dose
Number of subjects: 10
Study 7506878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7506878 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame (APM)
Number of subjects: 10
Study 3174150 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (10 mg)
Number of subjects: 12
Study 3174150 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg)
Number of subjects: 12
Study 3174150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 417375 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana intoxication
Number of subjects: 35
Study 417375 — intervention group
Group type: COMPARATOR
Intervention: Normal waking state (without marijuana)
Number of subjects: 35
Study 31722839 — intervention group
Group type: EXPERIMENTAL
Intervention: Rd (lenalidomide, dexamethasone)
Number of subjects: 1265
Study 31722839 — intervention group
Group type: EXPERIMENTAL
Intervention: Vd (bortezomib, dexamethasone)
Number of subjects: 1265
Study 31722839 — intervention group
Group type: COMPARATOR
Intervention: Control arm of hallmark RCTs
Number of subjects: 1265
Study 30315423 — intervention group
Group type: EXPERIMENTAL
Intervention: TiF4 varnish
Number of subjects: 60
Study 30315423 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraphat® (fluoride positive control)
Number of subjects: 60
Study 30315423 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish (no fluoride)
Number of subjects: 60
Study 30315423 — intervention group
Group type: COMPARATOR
Intervention: No treatment (negative control)
Number of subjects: 60
Study 28493912 — intervention group
Group type: COMPARATOR
Intervention: no-exercise control (n = 51)
Number of subjects: 171
Study 28493912 — intervention group
Group type: EXPERIMENTAL
Intervention: low-amount, low-intensity exercise (LALI, n = 38)
Number of subjects: 171
Study 28493912 — intervention group
Group type: EXPERIMENTAL
Intervention: high-amount, low-intensity exercise (HALI, n = 52)
Number of subjects: 171
Study 28493912 — intervention group
Group type: EXPERIMENTAL
Intervention: high-amount, high-intensity exercise (HAHI, n = 30)
Number of subjects: 171
Study 26114436 — intervention group
Group type: EXPERIMENTAL
Intervention: cART
Number of subjects: 836
Study 23616552 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory signals (audiovisual signals)
Number of subjects: 0
Study 23616552 — intervention group
Group type: COMPARATOR
Intervention: Unisensory conditions
Number of subjects: 0
Study 21267525 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 LCPUFA supplementation (2.5 g/day, with 1.67 grams of EPA and 0.83 grams of DHA)
Number of subjects: 46
Study 21267525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 19125899 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide + Metformin
Number of subjects: 248
Study 19125899 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide + Metformin
Number of subjects: 248
Study 17420152 — intervention group
Group type: EXPERIMENTAL
Intervention: comfilcon A
Number of subjects: 45
Study 17420152 — intervention group
Group type: COMPARATOR
Intervention: lotrafilcon A
Number of subjects: 45
Study 17420152 — intervention group
Group type: COMPARATOR
Intervention: balafilcon A
Number of subjects: 45
Study 15023101 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone infusion (0.5 microg.min(‐1).kg(‐1))
Number of subjects: 62
Study 15023101 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 62
Study 10694619 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g in 100 mL of saline solution)
Number of subjects: 40
Study 10694619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10694619 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 9179457 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6 (150 mg daily for 30 days)
Number of subjects: 124
Study 9179457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 8472140 — intervention group
Group type: EXPERIMENTAL
Intervention: Monofilament continuous absorbable sutures (Maxon)
Number of subjects: 988
Study 8472140 — intervention group
Group type: COMPARATOR
Intervention: Multifilament interrupted absorbable sutures (Vicryl)
Number of subjects: 988
Study 3911096 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg guanfacine hydrochloride (Estulic)
Number of subjects: 10
Study 3911096 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg guanfacine hydrochloride (Estulic)
Number of subjects: 10
Study 3911096 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg clonidine (Catapres)
Number of subjects: 10
Study 3911096 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg clonidine (Catapres)
Number of subjects: 10
Study 3911096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31176601 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant gemcitabine chemoradiation
Number of subjects: 71
Study 31176601 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete/marked response group
Number of subjects: 71
Study 31176601 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate response group
Number of subjects: 71
Study 31176601 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal response group
Number of subjects: 71
Study 31176601 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathologic complete responses
Number of subjects: 71
Study 29505517 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume hemofiltration (HVHF)
Number of subjects: 40
Study 29505517 — intervention group
Group type: COMPARATOR
Intervention: Control (fasting, decompression, intravenous somatostatin)
Number of subjects: 40
Study 26909012 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic treatment with ibuprofen
Number of subjects: 386
Study 26909012 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic treatment
Number of subjects: 386
Study 26909012 — intervention group
Group type: COMPARATOR
Intervention: Non-antibiotic treatment
Number of subjects: 386
Study 24925675 — intervention group
Group type: EXPERIMENTAL
Intervention: RYO cigarettes
Number of subjects: 77
Study 24925675 — intervention group
Group type: EXPERIMENTAL
Intervention: PMM cigarettes
Number of subjects: 77
Study 24925675 — intervention group
Group type: EXPERIMENTAL
Intervention: FM cigarettes
Number of subjects: 77
Study 24925675 — intervention group
Group type: EXPERIMENTAL
Intervention: All cigarette types
Number of subjects: 77
Study 24925675 — intervention group
Group type: EXPERIMENTAL
Intervention: MYO cigarettes (RYO and PMM)
Number of subjects: 77
Study 24925675 — intervention group
Group type: EXPERIMENTAL
Intervention: MYO and FM cigarettes
Number of subjects: 77
Study 22845032 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV education, peer video, motivational interviewing, behavioral skills training
Number of subjects: 73
Study 22845032 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 73
Study 21071584 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-guided 'Constant-care' approach
Number of subjects: 333
Study 21071584 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 333
Study 18265663 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligasure electrocautery device
Number of subjects: 116
Study 16373244 — intervention group
Group type: EXPERIMENTAL
Intervention: Red clover isoflavone supplement (80 mg/day)
Number of subjects: 60
Study 16373244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12196430 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic and community intervention (group A)
Number of subjects: 200
Study 12196430 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic only intervention (group B)
Number of subjects: 200
Study 9568917 — intervention group
Group type: EXPERIMENTAL
Intervention: Febrile episodes
Number of subjects: 180
Study 9568917 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in temperature (Celsius) during subsequent infections
Number of subjects: 180
Study 9568917 — intervention group
Group type: COMPARATOR
Intervention: Age, sex, type of initial seizure, temperature during initial seizure, family history of febrile seizures or epilepsy
Number of subjects: 180
Study 8534629 — intervention group
Group type: EXPERIMENTAL
Intervention: Kabi 2161 (600 mg) tablets, 1 four times daily
Number of subjects: 68
Study 8534629 — intervention group
Group type: EXPERIMENTAL
Intervention: Kabi 2161 (600 mg) tablets, 2 twice daily
Number of subjects: 68
Study 8534629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 1978612 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 1 mg/kg
Number of subjects: 40
Study 1978612 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 1.5 mg/kg
Number of subjects: 40
Study 1978612 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 2 mg/kg
Number of subjects: 40
Study 1978612 — intervention group
Group type: COMPARATOR
Intervention: Control group (no esmolol)
Number of subjects: 40
Study 64653 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin analogue
Number of subjects: 0
Study 64653 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 0
Study 30747746 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular training (NMT)
Number of subjects: 28
Study 30747746 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 31605312 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Number of subjects: 158
Study 31605312 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 158
Study 31012933 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented nurse home visitation program with IPV intervention (n=229 participants)
Number of subjects: 492
Study 31012933 — intervention group
Group type: COMPARATOR
Intervention: Standard nurse home visitation program (n=263 participants)
Number of subjects: 492
Study 31012933 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Augmented and Standard)
Number of subjects: 492
Study 28589749 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib
Number of subjects: 676
Study 28589749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 676
Study 25765456 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 s treatment
Number of subjects: 16
Study 25765456 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 min treatment
Number of subjects: 16
Study 25765456 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 min treatment
Number of subjects: 16
Study 25765456 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 16
Study 23719582 — intervention group
Group type: EXPERIMENTAL
Intervention: ARCON (accelerated radiotherapy with carbogen breathing and nicotinamide)
Number of subjects: 261
Study 23719582 — intervention group
Group type: COMPARATOR
Intervention: AR (accelerated radiotherapy alone)
Number of subjects: 261
Study 23719582 — intervention group
Group type: EXPERIMENTAL
Intervention: ARCON
Number of subjects: 261
Study 21827652 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest compressions with good quality (compression depth ≥ 40 mm, compression rate 100‐120/minute)
Number of subjects: 57
Study 21827652 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest compressions with bad quality (initial compression depth < 40 mm, initial compression rate < 100 or > 120/minute)
Number of subjects: 57
Study 21827652 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest compressions with decay (change from good to bad during the 12 minutes)
Number of subjects: 57
Study 21827652 — intervention group
Group type: EXPERIMENTAL
Intervention: No-flow ratio (NFR) during ALS
Number of subjects: 57
Study 21827652 — intervention group
Group type: EXPERIMENTAL
Intervention: Decay of chest compression quality within the first two minutes
Number of subjects: 57
Study 19273696 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and cisplatin with fluorouracil (PCF)
Number of subjects: 78
Study 19273696 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and cisplatin without fluorouracil (PC)
Number of subjects: 78
Study 19273696 — intervention group
Group type: COMPARATOR
Intervention: INT0116 (standard treatment)
Number of subjects: 78
Study 18090457 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 200
Study 18090457 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 200
Study 18090457 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 200
Study 18090457 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 200
Study 18090457 — intervention group
Group type: COMPARATOR
Intervention: All SSRIs
Number of subjects: 200
Study 15673181 — intervention group
Group type: EXPERIMENTAL
Intervention: Rote rehearsal during divided attention
Number of subjects: 0
Study 15673181 — intervention group
Group type: EXPERIMENTAL
Intervention: Rote rehearsal
Number of subjects: 0
Study 11246607 — intervention group
Group type: EXPERIMENTAL
Intervention: Low microparticle diet (n = 10)
Number of subjects: 20